Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Foxp3+ T-regulatory (Treg) cells are known to suppress protective host immune responses to a wide variety of solid tumors, but their therapeutic targeting is largely restricted to their transient depletion or "secondary" modulation, e.g. using anti-CTLA-4 monoclonal antibody. Our ongoing studies of the post-translational modifications that regulate Foxp3 demonstrated that the histone/protein acetyltransferase, Tip60, plays a dominant role in promoting acetylation, dimerization and function in Treg cells. We now show that the ubiquitin-specific protease, Usp7, controls Treg function largely by stabilizing the expression and promoting the multimerization of Tip60 and Foxp3. Genetic or pharmacologic targeting of Usp7 impairs Foxp3+ Treg suppressive functions, while conventional T cell responses remain intact. As a result, pharmacologic inhibitors of Usp7 can limit tumor growth in immunocompetent mice, and promote the efficacy of antitumor vaccines and immune checkpoint therapy with anti-PD1 monoclonal antibody in murine models. Hence, pharmacologic therapy with Usp7 inhibitors may have an important role in future cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586 · cited 1×
“CD4cre mice (Lee et al., 2001), Foxp3YFP-cre mice (Rubtsov et al., 2008), Foxp3eGFP-Cre-ERT2 mice (Rubtsov et al., 2010), Tip60fl/fl mice (Xiao et al., 2014), and Usp7fl/flmice (Kon et al., 2011) were described previously.”
Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.
Reyes-Turcu, F. E., Ventii, K. H., & Wilkinson, K. D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082307.091526 · Cited by 1,396 · cited 4×
“Of the N50 mammalian USPs (Reyes-Turcu et al., 2009), some 21 USPs were detected in human Tregs and identified by ChIP studies as possible targets of FOXP3 (Sadlon et al.”
InfluentialCancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 1×
“Tumors have distinctive properties of growth, invasion andmetastasis (Hanahan and Weinberg, 2000), and the ability to evade immune destruction (Zitvogel et al., 2006).”
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944 · cited 3×
“In experimental tumor models, beneficial strategies include depletion of Foxp3+ Tregs using CD4 or CD25 mAb, cyclophosphamide, IL-2-coupled toxin, or diphtheria-coupled toxin in so-called DEREG mice; use of agents that affect Treg development such as COX-2/PGE2, TGF-β, aromatase, STAT3 or p38 MAPK inhibitors, and TLR…”
MethodInfluentialStability of the Regulatory T Cell Lineage in Vivo
Rubtsov, Y. P., Niec, R. E., Josefowicz, S., Li, L., Darce, J., Mathis, D., Benoist, C., & Rudensky, A. Y. (2010) · Science · doi:10.1126/science.1191996 · Cited by 730 · cited 2×
“CD4cre mice (Lee et al., 2001), Foxp3YFP-cre mice (Rubtsov et al., 2008), Foxp3eGFP-Cre-ERT2 mice (Rubtsov et al., 2010), Tip60fl/fl mice (Xiao et al., 2014), and Usp7fl/flmice (Kon et al., 2011) were described previously.”
A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679 · cited 3×
“We now report that both Tip60 and Foxp3 proteins are subject to ubiquitination and proteasomal degradation, whereas the actions of a deubiquitinating (DUB) enzyme, ubiquitin-specific protease, Usp7 (also known as HAUSP) (Cummins et al., 2004; Li et al., 2004),”
Self-citationChauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 5×
“To assess whether pharmacologic blockade of Usp7 could modulate normal Foxp3+ Treg cell function, we evaluated several highly selective small molecule inhibitors of Usp7 (Usp7i), including the parent compound P5091, and its derivative P0217564 (hereafter 564) (Chauhan et al., 2012; Weinstock et al., 2012), whose poten…”
InfluentialSelf-citationDisruption of HAUSP gene stabilizes p53.
Cummins, J. M., Rago, C., Kohli, M., Kinzler, K. W., Lengauer, C., & Vogelstein, B. (2004) · Nature · doi:10.1038/nature02501 · Cited by 379 · cited 2×
“…and proteasomal degradation, whereas the actions of a deubiquitinating (DUB) enzyme, ubiquitin-specific protease, Usp7 (also known as HAUSP) (Cummins et al., 2004; Li et al., 2004), counteract these events and promote Tip60 and Foxp3 stability and, consequently, Treg suppressive function.”
Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47.
Weinstock, J., Wu, J., Cao, P., Kingsbury, W. D., McDermott, J. L., Kodrasov, M. P., McKelvey, D. M., Suresh Kumar, K. G., Goldenberg, S. J., Mattern, M. R., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200276j · Cited by 187 · cited 3×
“…Foxp3+ Treg cell function, we evaluated several highly selective small molecule inhibitors of Usp7 (Usp7i), including the parent compound P5091, and its derivative P0217564 (hereafter 564) (Chauhan et al., 2012; Weinstock et al., 2012), whose potencies and specificities are summarized in Table S3.”
Self-citationDeubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway.
Dar, A., Shibata, E., & Dutta, A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00358-13 · Cited by 83
Roles of HAUSP-mediated p53 regulation in central nervous system development
Kon, N., Zhong, J., Kobayashi, Y., Li, M., Szabolcs, M., Ludwig, T., Canoll, P. D., & Gu, W. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.12 · Cited by 79 · cited 3×
“We also analyzed the effects ofUsp7deletion on the in vitro development of inducible Tregs (iTregs) using Usp7−/− conventional T cells, obtained bymating CD4cre and Usp7fl/flmice.”
Method
Cited by
Regulatory T cells in autoimmune disease
Dominguez-Villar, M., & Hafler, D. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0120-4 · Cited by 713
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
The regulation of immune tolerance by FOXP3
Lu, L., Barbi, J., & Pan, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.75 · Cited by 580
Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463
USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.-P., Prakash, S., et al. (2017) · Nature · doi:10.1038/nature24006 · Cited by 333
Metadata
- Authors
- Wang, L., Kumar, S., Dahiya, S., Wang, F., Wu, J., Newick, K., Han, R., Samanta, A., Beier, U. H., Akimova, T., Bhatti, T. R., Nicholson, B., Kodrasov, M. P., Agarwal, S., Sterner, D. E., Gu, W., Weinstock, J., Butt, T. R., Albelda, S. M., & Hancock, W. W.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 13
- Pages
- 99-112
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2538711772
- Cited by
- 120
- References
- 12
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.